Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
暂无分享,去创建一个
Serge Leyvraz | Herve Avet-Loiseau | Philippe Moreau | Chantal Doyen | Brigitte Pegourie | J. Bourhis | B. Pégourié | S. Leyvraz | C. Dumontet | P. Moreau | H. Avet-Loiseau | G. Marit | T. Facon | J. Harousseau | C. Doyen | M. Attal | C. Berthou | L. Garderet | L. Benboubker | C. Hulin | D. Caillot | Thierry Facon | Charles Dumontet | Laurent Garderet | Jean-Luc Harousseau | Michel Attal | Gerald Marit | Cyrille Hulin | Lofti Benboubker | Ibrahim Yakoub Agha | Jean-Henri Bourhis | Marc Renaud | Laurent Voillat | Christian Berthou | Mathieu Monconduit | Denis Caillot | Bernard Grobois | L. Voillat | M. Renaud | M. Monconduit | I. yakoub Agha | B. Grobois | I. Yakoub Agha
[1] P. Ravaud,et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. , 1998, Blood.
[2] H. Ludwig,et al. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] P. Ravaud,et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Moreau,et al. A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials. , 2005 .
[5] D. Esseltine,et al. A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients. , 2004 .
[6] A. Willan,et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. , 1988, British Journal of Cancer.
[7] D. Weber,et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[9] S. Schey. Thalidomide in the Management of Multiple Myeloma , 2002, Hematology.
[10] K. Ding,et al. Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant , 2004, Clinical Cancer Research.
[11] Robert A Kyle,et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Largman,et al. The HOX-MEIS connection in AML , 2005 .
[13] J. S. San Miguel,et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. , 2005, Blood.
[14] R. Coleman,et al. Osteoclast inhibition for the treatment of bone metastases. , 1993, Cancer treatment reviews.
[15] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[16] Brigitte Pegourie,et al. Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma. , 2005 .
[17] References , 1971 .
[18] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[19] John Crowley,et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.
[20] K. Ding,et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute Of Canada Clinical Trials Group Study: MY.7. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Foà,et al. Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. , 2006 .
[22] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[23] J. Crowley,et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. , 2002, Blood.
[24] Remission maintenance therapy for multiple myeloma. , 1975, Archives of internal medicine.
[25] Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients , 2001, British journal of haematology.
[26] J. Rossi,et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.
[27] Vincenzo Callea,et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.
[28] Jerome B. Zeldis,et al. Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). , 2005 .
[29] F. Mandelli,et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. , 2004, Blood.
[30] M. Kovacs,et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.
[31] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.